Suivant

Lecture automatique

Novel targets in the treatment of CTCL

2 Vues • 08/09/23
Partager
Intégrer
administrator
administrator
Les abonnés
0

Jan P. Nicolay, MD, Ruprecht Karls University of Heidelberg, Mannheim, Germany, gives an overview of novel drug targets being investigated for the treatment of cutaneous T-cell lymphoma (CTCL), in particular commenting on the CD30 pathway and the role BCL-2. Dr Nicolay also describes synergistic effect of inhibition of BCL-2 in combination with dimethyl fumarate (DMF). This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Montre plus
0 commentaires sort Trier par
Commentaires de Facebook

Suivant

Lecture automatique